ELIONOVA, the Haute école d’ingénierie et d’architecture, and the University of Fribourg have received CHF 480,000 in funding from Innosuisse, the Swiss Innovation Agency, for a joint project to develop a comprehensive blood test for sepsis.

With a significant contribution to the advancement of the Medtech industry, the Haute école d’ingénierie et d’architecture and the University of Fribourg, together with ELIONOVA as an implementation partner, have secured substantial funding of CHF 480,000 for their research partners. Innosuisse supports SMEs, startups, and other Swiss organizations in their R&D activities.

With the acquired funding, ELIONOVA continues the development of its EVA technology and aims to expand into further markets. In emergency medicine, Elionova's high-precision diagnostic technology at the point of care improves the early detection of septic patients—a key factor for more efficient treatment and better patient outcomes.